QR-koda

Enteric Budesonide Treatment in IgA Nephropathy

Introduction: Targeted release formulation (TRF)-budesonide was the first drug approved by regulatory authorities for the management of IgA nephropathy (IgAN) but is not available in many countries. Enteric coated (EC)-budesonide is widely available, but there is a paucity of data in IgAN. Methods:...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Sanjeev Gulati, Arpita Roy Chaudhary, Sanshriti Chauhan, Karan Saraf, Dinesh Khullar, Sanjiv Jasuja, Vinay Rathore, Hari Shankar Meshram, Brad Rovin
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Elsevier 2026-05-01
Ráidu:Kidney International Reports
Fáttát:
end- stage kidney disease
IgA nephropathy
infection
oral budesonide
proteinuria
Liŋkkat:http://www.sciencedirect.com/science/article/pii/S2468024926026434
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid